Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970912 | 0.89 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL7393652 | 0.89 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL4814264 | 0.89 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL379160 | 0.89 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| Bicarbonate SCHEMBL4357688 | 0.87 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL15011579 | 0.87 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL15447435 | 0.86 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL6388570 | 0.85 | MEN1 (0.62) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL8989897 | 0.85 | MEN1 (0.62) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A | |
| SCHEMBL15709327 | 0.85 | L3MBTL1 (0.63) | MEN1KMT2ANPSR1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2452939-B1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | YANG JI CHEMICAL CO LTD (KR) | 2014-03-26 | — | — | EP | disclosed |
| US-8575173-B2 | Piperazinyl 3-aminopyrrolidine derivatives as a CCR2 antagonists | YANG JI CHEMICAL CO., LTD. (KR) | 2013-11-05 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120190689-A1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | YANG JI CHEMICAL CO., LTD. (KR) | 2012-07-26 | — | — | US | disclosed |
| EP-2452939-A2 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | Yang Ji Chemical Co., Ltd. (KR) | 2012-05-16 | — | — | EP | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-5922868-A | 1-(4,4-ETHYLENEDIOXY-3-METHYLPENTYL)-3-METHYL-7-PROPYLXANTHINE | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0570831-A2 | Use of Xanthinderivatives for treatment of cerebral nerve dammages after disruption of the blood circulation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | MEN1 2262/4885KMT2A 371/4885NPSR1 682/4885 |
| US-20120190689-A1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | CCR2, CCR1, CCR9 | MEN1 3798/4885KMT2A 1789/4885NPSR1 220/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | MEN1 231/4885KMT2A 216/4885NPSR1 2906/4885 |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | MEN1 4112/4885KMT2A 1389/4885NPSR1 4217/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | MEN1 2539/4885KMT2A 455/4885NPSR1 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.